Where MSCs Go When Injected And Why It Matters

Mesenchymal stem/stromal cells behave in dramatically different ways depending on how they enter the body. IV-delivered MSCs trigger rapid immune interactions in the lungs, where most cells undergo apoptosis within 24 hours after facing complement-mediated destruction. Their therapeutic benefit comes from this "die to heal" mechanism—apoptotic MSCs educate lung macrophages toward anti-inflammatory states that cascade systemically. Locally delivered MSCs tell an entirely different story. Protected from immediate blood contact, these cells persist as living biofactories that continuously secrete therapeutic molecules, can be engineered to release specific factors on demand, or differentiate into functional tissue.

Discover how emerging engineering strategies—including genetic modifications, priming protocols, and biomaterial scaffolds—are transforming MSC therapy from empirical guesswork into rational design. Learn which unanswered questions about MSC survival, potency mechanisms, and therapeutic cargo delivery will shape the next generation of treatments. The shift toward standardized cell banks, defined manufacturing processes, and targeted cellular modifications is creating reproducible platforms where MSCs can be programmed for specific therapeutic jobs rather than deployed with uncertain outcomes.